|

Androgen Receptor Pathway Inhibitors (ARPIs) Clinical Trials

2 actively recruiting trials

Also known as: Abiraterone acetate, Apalutamide, Darolutamide, Enzalutamide

Pipeline

Phase 2/3: 1

Top Sponsors

  • Ankara Etlik City Hospital1
  • Affidea Nu-med Center of Oncological DIagnostics and Therapy1

Indications

  • Cancer2
  • Regionally Advanced Prostate Cancer1
  • Dose Escalation: Solid Tumors1
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)1
  • Depression1

Other2 trials

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Phase 2/3
Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.